Ivosidenib | Servier (Agios) | ||
250 mg; Tablet |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
None |
Less Than 5
|
||
None | None | ||
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test | |||
Yes
|
Tibsovo | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 |
---|---|---|---|---|---|---|---|---|---|
******* | *** ********* | *** ********* | ******* ***** ******** ************ *** ******** | ******* ***** ******** ************ *** ******** | *** ********* | *** ********* | *** ********* | ******* ***** ******** ************ *** ******** | ******* ***** ******** ************ *** ******** |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
******* | *** \ ********* | *** **, **** | ******* | ********* ******** | ******* *** **** *** *** **** |